List view / Grid view
Researchers have discovered that the enzyme OTULIN, known for regulating the immune system, also drives the formation of tau – a protein linked to Alzheimer’s and other neurodegenerative diseases.
Scientists have captured, for the first time, dynamic changes in a crucial neuronal ‘master switch’ inside the living brain, potentially informing new future treatments for neurodegenerative diseases.
A recently developed experimental drug, called NU-9, has shown promise in targeting a toxic form of amyloid beta – halting Alzheimer’s disease before symptoms appear.
UVA researchers have discovered a potential treatment approach that restores the brain’s natural drainage system, offering hope for preventing traumatic brain injury-related neurodegeneration.
New research has shown that the enzyme OTULIN regulates tau at the gene-expression level rather than through protein degradation.
A naturally occurring amino acid commonly found in supplements has reduced harmful amyloid build-up and eased symptoms in animal models of Alzheimer’s disease.
Oxford-based techbio start-up Scripta Therapeutics has announced a $12 million seed funding round helping them to reshape conventional drug discovery.
Researchers have discovered that Alzheimer’s may disrupt communication between nerves and blood vessels in fat tissue which could explain why people with Alzheimer’s are often diagnosed with heart disease and metabolic problems.
New research from Johns Hopkins Medicine reveals that the enzyme BVRA protects brain cells from oxidative stress, allowing for potential new methods for treating neurodegenerative diseases like Alzheimer’s.
Scientists have developed two rapid and affordable blood tests that can detect early markers of Alzheimer’s disease – potentially decades before symptoms appear.
Scientists have used fruit flies to study 100 genes linked to Alzheimer’s disease and how these genes affect brain structure, function and stress resilience. The research could help guide new treatments in the future.
New preclinical data on ACI-19626, a first-in-class PET tracer for imaging TDP-43 pathology, shows potential to greatly improve early diagnosis and treatment of multiple neurodegenerative diseases.
New research has discovered how Rab proteins control the delivery of critical supplies to strengthen neural connections, providing researchers with important insights into memory formation and potential strategies for Alzheimer’s resilience.
Researchers have developed bioactive nanoparticles that restore the brain’s blood-brain barrier and clear toxic proteins, reversing Alzheimer’s symptoms in mice and offering a promising new approach to treating the disease.
Virginia Tech computer scientists have created a new AI tool, ProRNA3D-single, that can generate 3D models of how viral RNA binds to human proteins – a development that could speed up drug discovery.
